What is Ovagen used for in research discussions?

Ovagen is described in the source as a synthetic tripeptide, Glu-Asp-Leu or EDL, grouped with Khavinson-style peptide bioregulators. Reported interest centers on liver and gastrointestinal support claims, but the supplied evidence emphasizes that Ovagen-specific published data are sparse and that vendor claims exceed independently verified findings.

Is Ovagen FDA approved?

No. The supplied source states that Ovagen is not FDA approved and characterizes its evidence status as preclinical, with reported supplement approval in Russia.

What side effects are reported for Ovagen?

The source lists general tolerability, limited safety data outside Russia, and lack of FDA approval as safety-related notes. It does not provide robust adverse-event data from controlled human trials.

What dose is reported for Ovagen?

The source reports community use of 10-20 mg daily, once or twice daily, with oral capsules or sublingual administration. This is a source-reported community pattern, not a validated medical recommendation.

Bioregulators Preclinical - animal studies only

Ovagen

Also known as: Glu-Asp-Leu, EDL

At a glance

PeptiGuide dataset · reviewed Aug 2026

What it is

EDL peptide bioregulator discussed for liver and gastrointestinal research claims

Status

Preclinical

Evidence level: animal studies

Typical dose

10–20mg

Oral capsules or sublingual

Researched for

Liver support, GI health, detoxification

Trial progress

PrePreclinical
IPhase I
IIPhase II
IIIPhase III
IVPhase IV
FDAFDA approved

Preclinical - Promising animal research, limited human data

Use the tools

In plain language

Synthetic ultra-short identified as Glu-Asp-Leu (EDL).
Grouped with Khavinson-style peptide bioregulators and discussed around liver and gastrointestinal support claims.
Source status is , with no FDA approval and reported supplement approval in Russia.
Source-reported dosing is 10-20 mg daily, once or twice daily, by oral capsule or sublingual route.

How it's thought to work

Ovagen is proposed to fit the bioregulator model: a very short peptide, EDL, may be transported into cells and then affect gene transcription in a tissue-selective way. The source frames liver cells and gastrointestinal epithelium as claimed target tissues. It also cautions that this is an extrapolated hypothesis rather than a mechanism proven directly for Ovagen in independent studies.

What the research shows

Where the research stands

The supplied evidence places Ovagen within the broader Khavinson bioregulator category, where some publications discuss gene-expression or chromatin-related effects for other short peptides. For Ovagen or EDL specifically, the source describes the research base as thin, with claims about liver fibrosis or gut mucosa protection attributed mainly to marketing rather than controlled experiments. No registered human clinical trials or high-quality human efficacy evidence are identified in the supplied material.

What it shows

✓ Animal studies

Promising animal research, limited human data

△ Limitations

Animal study doses may not translate directly to humans.

Bottom line: Preclinical research; reportedly approved in Russia as a supplement Not FDA approved

Typical dosing

CommunityCommunity dataset

10–20 mg

daily

10 mgfull range seen20 mg

Community-reported use is framed around liver and gastrointestinal bioregulator claims; this is not clinical dosing guidance.

Research dosing

Animal studies onlyAnimal studies only - may not translate to humans

Doses observed in studies

10-20 mg daily

Animal study doses may not translate directly to humans.

Duration: 10-30 day cycles
Administration: Oral capsules or sublingual

Timing & administration

Best time to take

Morning on an empty stomach

Once or twice daily

Food recommendation

Take on an empty stomach

Why this timing?

The source links fasted use to absorption practices for peptide bioregulators, but does not provide Ovagen-specific clinical timing evidence.

Possible side effects

Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.

Generally well-tolerated
Limited safety data outside Russia
Not FDA approved

Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.

Sources

PubMed ClinicalTrials.gov FDA.gov

Frequently asked questions

The proposed model is extrapolated from the broader peptide bioregulator literature. Short peptides such as EDL are said to enter cells through peptide transport systems and may influence transcription in selected tissues. For Ovagen, the source notes liver cells and gastrointestinal epithelium as claimed targets, while also stating that this mechanism has not been independently demonstrated for Ovagen itself.

Sequence

H-Glu-Asp-Leu-OH (EDL)

One open dataset

Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.

Browse the dataset

Save to my research list Get updates on Ovagen

Educational resource, not medical advice. Talk to your clinician before acting on anything here.

Community discussion

Comments are moderated before they appear. Keep it evidence-focused.

Ovagen

In plain languageIn plain language

How it's thought to workHow it's thought to work

What the research showsWhat the research shows

Typical dosing

Research dosing

Timing & administrationTiming & administration

Possible side effectsPossible side effects

SourcesSources

Frequently asked questionsFrequently asked questions